---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000063"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-10T23:58:15.812922+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion completes Phase 1 study for REC-3964; drug well tolerated, Phase 2 planned for 2024

## Summary
- Phase 1 study of REC-3964 in healthy volunteers completed; no serious adverse events reported.
- 42 participants in MAD part; doses up to 900 mg for 14 days; PK dose-proportional, half-life 7-10 hrs.
- Treatment-related AEs in 11.8% (4/34) of REC-3964 recipients, all mild; no discontinuations.
- Phase 2 proof-of-concept trial in recurrent C. diff infection expected to start in 2024.
- REC-3964 is novel non-antibiotic small molecule inhibitor of C. diff toxins; >730k cases US/EU5 annually.

## SEC filing metadata
- accession: 0001601830-23-000063
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000063/0001601830-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000063/rxrx-20230905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000063
- JSON: https://secwatch.observer/filing/0001601830-23-000063.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.